TY - JOUR
T1 - Outcomes of living donor liver transplantation for hepatitis C virus-positive recipients in Japan
T2 - Results of a nationwide survey
AU - Akamatsu, Nobuhisa
AU - Sugawara, Yasuhiko
AU - Kokudo, Norihiro
AU - Eguchi, Susumu
AU - Fujiwara, Toshiyoshi
AU - Ohdan, Hideki
AU - Nagano, Hiroaki
AU - Taketomi, Akinobu
AU - Kitagawa, Yuko
AU - Shimada, Mitsuo
AU - Ku, Yonson
AU - Yanaga, Katsuhiko
AU - Shirabe, Ken
AU - Ikegami, Toru
AU - Mizokami, Masashi
AU - Takeuchi, Masahiro
AU - Maehara, Yoshihiko
PY - 2014/8
Y1 - 2014/8
N2 - A nationwide survey of living donor liver transplantation (LDLT) for hepatitis C virus (HCV)-positive recipients was performed in Japan. A total of 514 recipients are reported and included in the study. The cumulative patient survival rate at 5 and 10 years was 72% and 63%, respectively. Of the 514 recipients, 142 patients (28%) died until the end of the observation, among which the leading cause was recurrent hepatitis C (42 cases). According to Cox regression multivariate analysis, donor age (>40), non-right liver graft, acute rejection episode, and absence of a sustained virologic response were independent prognostic factors. Of the 514 recipients, 361 underwent antiviral treatment mainly with pegylated-interferon and ribavirin (preemptive treatment in 150 patients and treatment for confirmed recurrent hepatitis in 211). The dose reduction rate and discontinuation rate were 40% and 42%, respectively, with a sustained virologic response rate of 43%. In conclusion, patient survival of HCV-positive recipients after LDLT was good, with a 10-year survival of 63%. Right liver graft might be preferable for HCV-positive recipients in an LDLT setting.
AB - A nationwide survey of living donor liver transplantation (LDLT) for hepatitis C virus (HCV)-positive recipients was performed in Japan. A total of 514 recipients are reported and included in the study. The cumulative patient survival rate at 5 and 10 years was 72% and 63%, respectively. Of the 514 recipients, 142 patients (28%) died until the end of the observation, among which the leading cause was recurrent hepatitis C (42 cases). According to Cox regression multivariate analysis, donor age (>40), non-right liver graft, acute rejection episode, and absence of a sustained virologic response were independent prognostic factors. Of the 514 recipients, 361 underwent antiviral treatment mainly with pegylated-interferon and ribavirin (preemptive treatment in 150 patients and treatment for confirmed recurrent hepatitis in 211). The dose reduction rate and discontinuation rate were 40% and 42%, respectively, with a sustained virologic response rate of 43%. In conclusion, patient survival of HCV-positive recipients after LDLT was good, with a 10-year survival of 63%. Right liver graft might be preferable for HCV-positive recipients in an LDLT setting.
KW - hepatitis C virus
KW - living donor liver transplantation
KW - nationwide survey
UR - http://www.scopus.com/inward/record.url?scp=84904977201&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84904977201&partnerID=8YFLogxK
U2 - 10.1111/tri.12329
DO - 10.1111/tri.12329
M3 - Review article
C2 - 24684710
AN - SCOPUS:84904977201
SN - 0934-0874
VL - 27
SP - 767
EP - 774
JO - Transplant International
JF - Transplant International
IS - 8
ER -
